CTX Technology acquires new drug delivery tech; FDA to review topical-barrier cream;

> CTX Technology has acquired the IP, formulations and related data of Convoy Therapeutics. The drug delivery tech can apparently transport small and large molecules, including biologics, into the skin, and enable localized placement. It has both therapeutic and aesthetic applications. More

> The FDA agreed to review Cipher Pharmaceuticals' submission for Dermadexin topical-barrier cream under its 510(k) pathway for low- to moderate-risk medical devices. The candidate is intended to treat the skin disorder seborrheic dermatitis. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.